A New Era of AI In a Regulated Environment
Artificial Intelligence is rapidly transforming nearly every industry. From fraud detection and algorithmic trading in finance to personalized recommendations and dynamic pricing in retail, AI is reshaping how businesses operate. In manufacturing, it powers predictive maintenance, quality inspection, and automated robotics, while in transportation it enables autonomous vehicles, route optimization, and smart traffic systems. Across all sectors, AI-driven chatbots and virtual assistants are transforming customer service.
These technologies promise efficiency, scalability, and new business models. However, as AI systems become more embedded in critical processes, the potential impact of failures, bias, misuse, and security vulnerabilities grows significantly. This becomes particularly important in regulated industries - such as healthcare, finance, transportation, energy, and critical infrastructure — where AI decisions can directly affect human safety, fundamental rights, and societal trust.
The convergence of AI innovation and societal risk lies at the core of what the EU Artificial Intelligence Act seeks to regulate. This article focuses specifically on how the EU AI Act applies to regulated environments, and healthcare in particular, explaining the fundamentals of the regulation, the key risks it addresses, and the practical governance frameworks organizations must implement to remain compliant. In healthcare AI is now widely used for diagnostic imaging, clinical decision support, patient monitoring, operational optimization, and even robotic surgery. While these applications offer enormous potential to improve care, they also introduce risks that can result in patient harm if not properly controlled.
AI Risk Classes Under the EU AI Act
The EU AI Act officially entered into force in August 2024, with most obligations becoming fully applicable in August 2026. Unlike traditional technology regulations, the Act does not treat all AI equally. Instead, it classifies systems based on the level of harm they may cause.
At the highest level are unacceptable-risk AI practices, which are completely prohibited. Among the banned practices are manipulative AI techniques, social scoring systems, biometric categorization tools, emotion recognition in workplaces and schools, and real-time biometric surveillance in public spaces.
High-risk AI systems are those that the EU considers most likely to cause serious harm if something goes wrong. This category includes all AI that is built into products already subject to safety regulations, such as medical devices, vehicles, or industrial machinery, as well as AI used in sensitive situations listed in Annex III of the EU AI Act. These sensitive areas include healthcare, hiring and workforce management, education, essential public services, critical infrastructure, law enforcement, and justice. In simple terms, if an AI system can strongly influence important decisions about people’s health, safety, rights, or access to services, it will almost always be classified as high-risk and must meet strict regulatory requirements.
Limited-risk AI systems are regulated primarily through transparency obligations. In practice, this means that users must be made aware when content is created by AI or when they are interacting with an automated system, as is the case with chatbots and generative AI applications. Minimal-risk systems, such as spell checkers, basic recommendation tools, or simple automation features, face no new regulatory obligations.
Together, these risk categories illustrate the core philosophy of the EU AI Act: regulation is proportional to potential harm. While low-impact AI systems remain largely unrestricted, applications that influence safety, fundamental rights, and critical decisions are subject to increasingly strict controls. By placing regulated products and sensitive use cases firmly within the high-risk category, the EU ensures that the most impactful AI systems are governed through rigorous oversight, accountability, and continuous risk management. This risk-based structure forms the foundation for all compliance obligations introduced by the Act.
Understanding the risk categories is only the first step. The EU AI Act goes further by introducing concrete governance obligations that organizations must implement in practice.
Governance obligations
The EU AI Act explicitly requires organizations to identify and manage AI-specific risks across the entire lifecycle of these systems. Providers are primarily responsible for ensuring compliance before market entry, including building governance frameworks, validating systems, managing risks, and documenting performance. Deployers, on the other hand, are responsible for safe and compliant use after deployment. They must follow intended use instructions, maintain human oversight, ensure data quality, monitor real-world performance, and report incidents.
At the heart of the EU AI Act lies the requirement for a continuous risk management approach. Rather than treating risk assessment as a one-time compliance exercise, providers are expected to actively identify and manage AI-specific hazards such as bias, model drift, misuse, and automation bias throughout the entire lifecycle of the system. Risks must be evaluated from initial design through real-world deployment, with mitigation measures clearly defined and residual risks regularly reassessed. As the system evolves, risk controls must evolve with it. This lifecycle-driven approach closely mirrors the well-established risk management framework used in medical devices under ISO 14971.
Closely connected to risk management is the Act’s strong emphasis on data governance. Because AI systems learn and operate based on data, the quality and representativeness of training and validation datasets become critical for safety and fairness. Providers must demonstrate that their data reflects real-world populations and use cases, analyze potential bias or imbalance, maintain full traceability of data sources, and justify why specific datasets are appropriate. High model accuracy alone is no longer sufficient. Organisations must prove that data has been responsibly selected, managed, and monitored.
To support transparency and regulatory oversight, comprehensive technical documentation is required. This documentation must clearly describe how the AI system works, its intended purpose, how risks are controlled, and how performance has been validated. Regulators should be able to understand not only system outcomes but also the underlying logic, architecture, and safeguards.
Human oversight is another cornerstone of the EU AI Act. AI systems must be designed in a way that keeps humans meaningfully involved in decision-making, particularly in high-impact situations. This includes mechanisms for reviewing AI outputs, overriding automated decisions, and receiving alerts when anomalies occur. The goal is not to replace human judgment, but to ensure that AI supports and enhances it in a controlled and accountable manner.
Finally, providers are required to ensure that AI systems remain accurate, robust, and secure throughout their use. This involves setting clear performance thresholds, conducting stress testing, building resilience against model drift, and implementing strong cybersecurity measures to protect systems from manipulation or failure.
Compliance under the EU AI Act does not end once an AI system enters real-world use. Providers must operate structured post-market monitoring processes that continuously collect and assess performance data in real operational environments. Through ongoing oversight, organizations must detect emerging risks such as model drift, bias, misuse, and performance degradation. Serious incidents must be reported without delay, thoroughly investigated, and addressed through corrective actions. Deployers, including hospitals, clinics, and other organizations using AI systems in practice, carry parallel responsibilities. They must ensure that AI is used strictly according to its intended purpose, trained personnel provide effective human oversight, and a high-quality input data is maintained. In addition, deployers are expected to monitor real-world system behavior, retain operational logs to support audits and investigations, communicate transparently with affected users and workers, and promptly report incidents. Together, providers and deployers form a shared accountability model under the EU AI Act. Both parties hold legal responsibility for compliance and face significant penalties if obligations are not met.
Applying the EU AI Act in Real-World AI Systems
To illustrate how the EU AI Act operates in practice, consider an AI healthcare system used in radiology that analyzes CT, MRI, or X-ray images to flag suspected cancer, strokes, or fractures. Under the regulation, this type of system is clearly classified as high-risk due to its direct impact on clinical decision-making and patient safety.
In such projects, the Business Analyst plays a critical role in translating regulatory requirements, clinical needs, and technical capabilities into clear system requirements, risk controls, and governance processes. The BA works closely with clinicians, data scientists, regulatory specialists, and developers to ensure that risks are identified early and addressed throughout the AI lifecycle.
False negatives represent one of the most critical risks, where the AI system fails to detect clinically relevant conditions. This can result in delayed diagnoses and serious patient harm. From a governance perspective, the Business Analyst helps define requirements that ensure AI outputs remain advisory, with mandatory human review embedded into clinical workflows. The BA also supports the definition of performance thresholds that prioritize sensitivity for life-threatening conditions and ensures that monitoring requirements are specified to detect performance degradation over time. Additionally, fallback procedures are captured as operational requirements so that clinical teams know how to proceed if the AI system becomes unreliable or unavailable.
Bias in training data is another major risk, particularly when datasets are not representative of real-world populations or clinical scenarios, AI systems may perform unevenly across demographic groups. The Business Analyst contributes by eliciting and documenting data governance requirements, such as representativeness analysis, subgroup performance reporting, and data lineage traceability. By ensuring these controls are clearly defined and measurable, the BA helps transform regulatory expectations into practical implementation steps.
Automation bias presents a behavioral risk where clinicians may over-trust AI recommendations and reduce critical review. To mitigate this, Business Analysts collaborate with UX designers and clinical stakeholders to define workflow and interface requirements that enforce active confirmation of AI findings. They also ensure that explainability features, such as visual heatmaps and confidence indicators, are integrated into the system and that instructions for use (IFU) clearly describe limitations, expected errors, and misuse scenarios. Audit and logging requirements further support oversight and continuous improvement.
Model drift is another key concern. Over time, changes in imaging equipment, clinical protocols, hospital environments, or patient populations can degrade AI performance. The Business Analyst helps specify drift detection metrics, revalidation triggers, and version control processes as formal system requirements. By doing so, drift management becomes a built-in governance mechanism rather than an ad hoc technical activity.
Together, these risks and controls demonstrate why the EU AI Act requires continuous oversight rather than one-time validation. They also highlight the active involvement of the Business Analyst in regulated AI projects. By bridging regulation, clinical practice, and technical implementation, the BA ensures that compliance is not treated as a separate activity but is embedded directly into system design, workflows, and operational processes.
Final Reflections
The EU AI Act marks a profound shift in how artificial intelligence is governed, particularly within regulated industries such as healthcare. AI is no longer viewed simply as a technical innovation or a software feature. It is now treated as a high-impact system that demands structured risk management, robust data governance, continuous oversight, and clearly defined accountability across its entire lifecycle. For organizations operating in healthcare and other regulated environments, early investment in AI governance is no longer optional—it is essential. Those that proactively build compliance frameworks will not only meet regulatory expectations but will also strengthen trust, improve system reliability, and reduce long-term risk. With enforcement coming in 2026, the organizations that weave governance into their daily AI practices today will be the ones that thrive tomorrow—staying compliant while continuing to innovate responsibly.
Author: Iryna Sizikova
I have 18 years of experience in healthcare and software development, working both in Europe and the US and marketing medical products in over 120 countries.
I hold international certifications including PMP (Project Manager Professional) and PSPO II (Professional Scrum Product Owner), and I am currently pursuing CBAP (Certified Business Analysis Professional) certification.
My professional focus lies in developing and enhancing R&D processes, aligning them with industry standards, and scaling a unified approach to planning, design, and development across more than 40 Agile teams within the organization. In my current role as the Chapter Lead of the Business Analysis and Documentation, I develop and promote strategies that simplify regulatory compliance and accelerate
time to market for medical devices through effective business analysis.
I am an active member of the International Institute of Business Analysis (IIBA), and I contribute to the global BA community as a podcast guest, presenter, author of scientific publications, and BA Award judge. I am passionate about educating Business Analysts on medical software development, risk management, and regulatory compliance, and I enjoy sharing best practices and techniques worldwide.
A few personal facts: I speak four languages, like yoga, pickleball, and recently got my pilot license.